Transoral acid reflux surgery in the USA

 For some years now transoral acid reflux surgery has been available in Europe and other parts of the world through a revolutionary procedure called EsophyX. The pioneers of this acid reflux surgery EndoGastric Solutions are world leaders in natural orifice surgery products and procedures. Trials have been carried out in the USA results at the completion of a one year follow on have been outstanding. The trials where carried out on GERD patients in the phase two multicentre study for first generation transoral incisonless fundoplication procedure using the EsophyX device. The device is the first truly incisionless transoral surgical product to mimic the more invasive Nissen fundoplication or laparoscope fundoplication. The EsophyX device is used for substansive anatomical repair to the esophageal sphincter without incisions or internal dissection and is a front line surgical management tool for gastroesophageal reflux disease (GERD) patients.

In this statement "For years, the medical community has been looking for less invasive ways to treat GERD patients with acid reflux surgery to reduce their dependence on pharmaceuticals. Our department has studied the effects of these pharmaceuticals and is concerned that there are additional detrimental effects that should be avoided. EsophyX is an impressive technology with impressive results that advances the treatment of GERD a giant leap forward." Put forward by Dr. John Hunter, Professor and Chairman of the Department of Surgery at Oregon Health & Science University in Portland, Oregon

A demonstration of this new TIF technique carried out a live case course at OSU February 29th: by Dr. Scott Melvin, Professor of Surgery, Director of the Centre for Minimally Invasive Surgery and Chief of the Division of General & Gastrointestinal Surgery at The Ohio State University (OSU) Medical Centre. He stated "I am very impressed with the clinical results for EsophyX, including the reduction/elimination of hiatal hernia and reduction/elimination of esophagitis. These multi-centre study results confirm the 2 year outcomes seen in the first EsophyX study. With over 750 Natural Orifice Surgical cases performed to date, utilizing EndoGastric Solutions technology platforms, it is clear that TIF is a mainstream procedure that most advanced foregut surgeons should be incorporating into their clinical practice. Any surgeon considering being a natural orifice surgeon should come see the techniques and learn more at our course."

Dr. Todd Overcash, Medical Director of Bariatric and Minimally Invasive Surgery at Munroe Regional Medical Centre in Ocala, Florida, is the United States leader of NOS (Natural Orifice Surgery) procedures performed. He was among the first U.S. surgical teams that went to Europe last fall to train on this new technique. He has now performed more EsophyX procedures than any surgeon in the U.S. and states: "Having performed 38 advanced TIF procedures with the EsophyX device in the last three months, I can attest that this incisionless technique offers our patients a tremendous improvement in their quality of life. It allows them the ability to eat foods and beverages they could not tolerate before the procedure but, most importantly, it allows them to discontinue their use of GERD medications in the majority of cases, which is especially important for women in the face of osteoporosis. With no skin incisions, no cutting of vessels, and no dissection of the fundus, the EsophyX device represents a new era in antireflux treatment and offers patients an innovative, state-of-the-art surgical procedure that will allow them to no longer live their lives pill-to-pill."

This new acid reflux surgery  is revolutionary in that patients can go into and out of hospital as day care patients. Most surgeries where carried out with the earlier TIF1 procedure but now an already improved TIF2 technique for using EsophyX is sowing an even stronger outcome.

"We are very pleased with the outstanding results of our first two GERD clinical studies," states Thierry Thaure, CEO of EndoGastric Solutions (EGS) Inc. We are encouraged that surgeons and advanced surgical endoscopists are rapidly adopting these new incisionless procedures, as patients are demanding a permanent solution for their reflux disease in the face of failing pharmacological therapy."

This revolution in acid reflux disease treatment may be the perfect solution for those who have suffered for years without any real solution to the problem.

For more information about EndoGastric Solutions, Inc., EsophyX(TM) and StomaphyX(TM), please visit:

US: http://www.endogastricsolutions.com

EU: http://www.egseurope.eu

Other locations: http://www.egsglobal.net